- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02581514
Eosinophilia Diagnosis (EOSINOPHILIM)
Algorithm for the Early Diagnosis and Treatment of Patients With Eosinophilia
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine.
Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can be life-threatening Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied.
The aim of this study is to assess the feasibility of a diagnostic approach based on a decision algorithm in a group of patients with eosinophilia.
We assume that a procedure with a hierarchy of additional tests would increase the frequency of diagnosed cases while decreasing the time to diagnosis.
This procedure defined by an algorithm would even reduce the number of tests necessary to reach a diagnosis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine.
Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can be life-threatening
Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied.
The aim of this study is to assess the feasibility of a diagnostic approach based on a decision algorithm in a group of patients with eosinophilia.
The contribution to the diagnosis of a hierarchical strategy for prescribing additional tests , based on clinical examination as well as some simple diagnostic tests, has never been evaluated
We assume that a procedure with a hierarchy of additional tests would increase the frequency of diagnosed cases while decreasing the time to diagnosis.
This procedure defined by an algorithm would even reduce the number of tests necessary to reach a diagnosis.
All types of patients are tacked into account: those coming from the university hospital, referred by general practitioners or by other hospitals.
In addition we address the internal medicine patients ,but also those of Hematology and Infectious Diseases. A comparison of these various groups would be relevant, since disorders that may be different.
Once enrolled, the patient is drived by the investigator through the various steps and exams imposed by the algorithm.
Indeed, during 5 months (Day1 5, 43, 71 , 85 , 99 ,113 and month 5), patient is asked to comply to the various exams and assessment imposed by the algorithm and that should lead to a diagnosis
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Holy BEZANAHARY
- Phone Number: +33(0)5 55 04 92 21
- Email: h.bezanahary@wanadoo.fr
Study Locations
-
-
-
Limoges, France, 87000
- Recruiting
- Médecine Interne A
-
Contact:
- Holy BEZANAHARY, MD
- Email: holy.bezanahary@chu-limoges.fr
-
Principal Investigator:
- Holy BEZANAHARY
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patient having one of the three following criteria:
- hypereosinophilia> 1500 / mm3, checked on at least two samples (interval between 2 samples at the discretion of the clinician)
- or hypereosinophilia> 500 cells / mm3 and organ damage with infiltration NCB proven by pathological examination,
- or hypereosinophilia> 500 cells / mm3 and found consistently for at least six months (present on all controls carried out before inclusion).
- Patient affiliated or beneficiary of a social security system
- Patient who signed the informed consent
Exclusion Criteria:
- Patient with solid tumors known (under chemotherapy or planned)
- Patient unable to understand or to adhere to the Protocol
- Patient unable to give consent
- Pregnant or breastfeeding women
- Patient already participating in an interventional trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Algorithm
Eosinophilia is assessed following the diagnosis algorithm
|
Scheduled exams and diagnosis circuit as imposed by the algorithm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients having correctly follow the diagnosis algorithm
Time Frame: 5 months
|
This outcome measure how many patients have correctly followed the diagnosis algorithm
|
5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of diagnosis
Time Frame: 5 months
|
Evaluate the rate of diagnosis using our diagnosis algorithm
|
5 months
|
Assess the time to diagnosis
Time Frame: 5 months
|
Assess the time to diagnosis
|
5 months
|
Description of diagnosis
Time Frame: 5 months
|
To compare the diagnosis found in our study to the published cohort.
|
5 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Holy BEZANAHARY, University Hospital, Limoges
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- I14028/EOSINOPHILIM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypereosinophilic Syndrome
-
Novartis PharmaceuticalsNo longer availableHypereosinophilic Syndrome (HES)
-
AstraZenecaRecruitingHypereosinophilic Syndrome (HES)United States
-
GlaxoSmithKlineRecruitingHypereosinophilic SyndromeUnited States, Argentina, Spain, Turkey, Israel, Brazil, Mexico, United Kingdom
-
National Institute of Allergy and Infectious Diseases...Knopp BiosciencesUnknownHypereosinophilic SyndromeUnited States
-
GlaxoSmithKlineTerminatedHypereosinophilic SyndromeUnited States, Belgium, Canada, Germany, Italy, France, Australia
-
GlaxoSmithKlineCompletedHypereosinophilic Syndrome | HypereosinophiliaUnited States, Belgium, Canada, Germany, Italy, France, Switzerland, Australia
-
GlaxoSmithKlineRecruitingHypereosinophilic SyndromeUnited States, Italy, Japan, Spain, Argentina, Belgium, China, Korea, Republic of, Czechia, Germany, Israel, Denmark, Poland, Brazil, Greece, Turkey, Mexico, Australia, Hong Kong, Romania, United Kingdom
-
AstraZenecaRecruitingHypereosinophilic SyndromeUnited States, Spain, Poland, Belgium, India, Japan, Italy, France, Germany, Austria, Denmark, Israel, Netherlands, Switzerland, Korea, Republic of, United Kingdom
-
University Hospital, LilleRecruitingEosinophilia | Hypereosinophilic SyndromeFrance
-
Novartis PharmaceuticalsTerminatedHypereosinophilic SyndromeBelgium
Clinical Trials on Scheduled exams and diagnosis
-
Imagine InstituteHopital Universitaire Robert-DebreCompletedSickle Cell DiseaseFrance
-
University Hospital, MontpellierRecruiting
-
Nationwide Children's HospitalTerminated
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital HypothyroidismFrance
-
Istituto Ortopedico RizzoliCompletedGroup IdentificationItaly
-
Nanjing Shihejiyin Technology, Inc.Recruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of UtahBlue Earth DiagnosticsTerminatedBrain TumorUnited States
-
French National Agency for Research on AIDS and...CompletedHIV Infection | Young AdultFrance
-
University Hospital, ToulouseNot yet recruiting